NCT01408225 Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
| NCT ID | NCT01408225 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Plasma Cell Dyscrasias |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2011-03-17 |
| Primary Completion | 2050-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2011-03-17 with a primary completion date of 2050-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals: * Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live. * Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups. * Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.
Eligibility Criteria
Inclusion: Diagnosis of a plasma cell dyscrasia Exclusion: Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.
Contact & Investigator
The Ohio State University Comprehensive Cancer Center
✉ OSUCCCClinicaltrials@osumc.edu📞 1-800-293-5066
Don Benson, MD
PRINCIPAL INVESTIGATOR
Ohio State University
Frequently Asked Questions
Who can join the NCT01408225 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Plasma Cell Dyscrasias. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01408225 currently recruiting?
Yes, NCT01408225 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT01408225 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT01408225 clinical trial?
NCT01408225 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Don Benson, MD at Ohio State University. The trial plans to enroll 5,000 participants.